4 results
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
Primary To determine the efficacy of REG1 compared to bivalirudin in patients with coronary artery disease (CAD) undergoing Percutaneous Coronary Intervention (PCI) for preventing the composite of death, nonfatal myocardial infarction, nonfatal…
The aim of this study is to find out if a percutaneous angioplasty can be carried out safely in patients who received a therapeutic dose of Desirudin (Revasc®) before the operation.
Primary objective: to evaluate the tolerability of the combination of RAD001 with radiotherapy.Secondary objective(s) To determine the antitumor activity of the combination of RAD001 (EVEROLIMUS) and radiotherapy (CR+PR+SD). To determine the…